Bat­tered and out of op­tions, His­to­gen­ics turns to eye drug de­vel­op­er Ocu­gen for re­verse merg­er

Mi­cro­cap com­pa­ny His­to­gen­ics has man­aged to stir up a fi­nal ral­ly around its stock be­fore it’s rel­e­gat­ed to the biotech his­to­ry books.

Malvern, PA-based Ocu­gen, a de­vel­op­er of gene ther­a­pies and oth­er bi­o­log­ics for rare eye dis­eases, has struck a re­verse merg­er deal with the strug­gling His­to­gen­ics. Its shares $HS­GX rose as much as 144% — though that trans­lates to pen­nies in the His­to­gen­ics’ world.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER